In vitro activity of tigecycline against multidrug-resistant Gram-negative blood culture isolates from critically ill patients represents a new therapeutic alternative. Tigecycline (a 9-t-butylglycylamide derivative of minocycline) is a glycylcycline antimicrobial agent having potent in vitro activity against most of the multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria, except for Pseudomonas aeruginosa and Proteae. 1, 2 Moreover, tigecycline is not affected by the mechanisms of resistance to tetracycline (efflux and ribosomal protection). 3 As in other tertiary care hospitals in India, drug resistance in bacteria has been an obstacle to treatment in intensive care units. Carbapenems have been the last resort in treating MDR Gram-negative infections. An increase in carbapenem resistance in Gram-negative organisms has also been noted recently. 3 This study was conducted to evaluate the in vitro activity of tigecycline against extended-spectrum b-lactamase (ESBL)producing and/or MDR Gram-negative bacteria isolated from the blood of critically ill patients.
From May 2010 to February 2011, blood culture was performed using the automated BacT/Alert blood culture system (bioMérieux, Marcy l'Étoile, France) from 827 critically ill patients admitted to the intensive care unit of St John's Medical College and Hospital, Bangalore, India. Only one isolate per patient was included. Non-repetitive Gram-negative bacilli (n¼ 69; 8.34%) were isolated from 827 patients. The isolates were identified as Escherichia coli (n¼20), Klebsiella pneumoniae (n¼9), Enterobacter cloacae (n¼ 2), Proteus mirabilis (n¼ 2), Serratia marcescens (n¼ 1), Citrobacter koseri (n¼ 1), Acinetobacter baumannii (n ¼18), Acinetobacter lwoffii (n¼ 1), Pseudomonas aeruginosa (n¼ 11), Pseudomonas putida (n ¼1), Achromobacter xylosoxidans (n¼ 2) and Chromobacterium indologenes (n¼ 1), using routine phenotypic microbiological methods and an automated identification system (VITEK 2, bioMérieux).
MICs of antibiotics were determined using an automated system (VITEK 2), following the manufacturer's guidelines. For analysis of in vitro activity of tigecycline, ESBL-producing strains of Enterobacteriaceae [85% of the E. coli (n¼ 17) and 77.8% of the K. pneumoniae (n ¼7)] and MDR (resistant to at least three classes of commonly used antimicrobials) strains of nonfermenting Gram-negative bacteria [84.2% of the Acinetobacter spp. (n¼ 16) and 100% of the Pseudomonas spp. (n¼ 12)] were included. ESBL production for Enterobacteriaceae was determined by the VITEK 2 ESBL confirmation test (AST-GN25 card; bioMérieux) and/or double disc synergy test using cefotaxime and cefotaxime/clavulanic acid discs. For tigecycline a susceptibility breakpoint of ≤2 mg/L was applied for all the Gram-negative isolates, according to CLSI guidelines. The study was approved by the institutional ethics review board of St John's Medical College and Hospital, Bangalore, India.
Tigecycline showed good potency, inhibiting 100% of the ESBL-producing E. coli, 85.7% of the ESBL-producing K. pneumoniae and 93.7% of the MDR A. baumannii at a concentration of ≤2 mg/L ( Table 1) . A tigecycline MIC 90 of 2 mg/L was noted for A. baumannii, a result similar to those of other studies. 4, 5 As expected, 100% of the P. aeruginosa (MIC 50 and MIC 90 of 16 mg/L) and Proteus mirabilis showed resistance to tigecycline, irrespective of being MDR or not. However, a single strain of MDR P. putida isolated was susceptible to tigecycline (MIC 2 mg/L). It should be noted that the MIC 90 for K. pneumoniae was higher compared with the other Enterobacteriaceae tested, as also observed by Souli et al. 6 Carbapenem resistance was observed in 28.6% of ESBL-producing K. pneumoniae, 100% of MDR Acinetobacter spp. and 66.7% of MDR Pseudomonas spp. The results of our study support the previous studies showing good in vitro activity of tigecycline against MDR organisms, 1,5,6 with a few exceptions. 3 Good in vitro potency of tigecycline was observed against ESBL-producing E. coli, K. pneumoniae and MDR Acinetobacter spp. Tigecycline can play a key role in tackling MDR organisms in the critical care units of tertiary care hospitals. In a prospective study, the CNS was found to be involved in 38.5% of the cases. 1 Treatment is not always successful. 2 -6 Co-trimoxazole (trimethoprim/sulfamethoxazole) has been reported to be significantly more effective than tetracycline; 2 however, resistance to co-trimoxazole has also been observed. 2 -6 More recently, there have even been reports describing resistance of CNS infections to treatment with ceftriaxone, a bactericidal antibiotic penetrating the blood -brain barrier. 1, 7 In 2002, a patient presented with diarrhoea, weight loss to 64 kg, anaemia (8.4 g/dL haemoglobin) and erythrocyte sedimentation rate of 33 mm/h. The medical history revealed relapsing arthritis since 1991 and pericarditis necessitating pericardial resection in 1993. Gastrointestinal biopsies disclosed periodic acid-Schiff (PAS)-positive macrophages typical of untreated Whipple's disease in the mucosa of the duodenum and the ileum and in the submucosa of the colon. The patient had no cerebral symptoms. However, microscopic examination of centrifuged CSF obtained by spinal puncture showed a PASpositive macrophage typical of Whipple's disease (histopathology carried out by Dr Reinhard Golz, Wuppertal), and the PCR to T. whipplei in the CSF was positive. The patient was admitted to a prospective treatment trial, as reported in Feurle et al. 1 He was randomized to 2 g of ceftriaxone infused intravenously once daily for 2 weeks, followed by oral co-trimoxazole at a dosage of 160/300 mg twice daily for 12 months. While the patient recovered from all signs and symptoms of Whipple's disease, the PCR for T. whipplei remained positive in the CSF for 5.5 years despite additional treatment with 1 g of meropenem infused intravenously thrice daily for 2 weeks followed by co-trimoxazole for another year. 1 After a further year of co-trimoxazole, the CSF was still positive in the T. whipplei PCR, while the patient was receiving this treatment. PAS-positive macrophages in duodenal mucosal biopsies and in the CSF had disappeared. CT and magnetic resonance imaging of the brain did not reveal any structural abnormality. At this time, the patient had no symptoms of systemic or cerebral Whipple's disease.
The presence of T. whipplei in the CSF was confirmed by sequence analysis of the amplification product, and the viability was established by culture in MRC5 fibroblasts and in axenic medium. In vitro susceptibility of the cultured strain to ceftriaxone, meropenem, tetracyclines and co-trimoxazole is shown in Table 1 . The risk of this patient developing symptomatic cerebral disease seemed unpredictable. After obtaining written informed consent for an individual treatment attempt, this patient was treated with chloroquine and tetracycline, a combination suggested previously. 8 Chloroquine (or hydroxychloroquine) enhances antimicrobial activity of tetracyclines by raising the pH of the phagolysosomes within macrophages. 8 Minocycline was selected as the tetracycline in this case as this compound has been reported to cross the blood -brain barrier well. 9,10 Pollock et al., 11 taking advantage of this pharmacokinetic property, were probably the first to treat a patient with cerebral Whipple's disease with minocycline. They did not combine it with chloroquine. Others prefer the combination of doxycycline and chloroquine. 6 In the present study, the dosage of chloroquine, based on a body weight of 83 kg, was 1725 mg of chloroquine phosphate in divided doses orally on day 1, and 575 mg on the second to the fourth day, followed by one 250 mg chloroquine phosphate tablet once daily for 45 days. A serum concentration of 165 mg/ L chloroquine (therapeutic range 20 to 200 mg/L) was obtained. Minocycline was given at a dosage of one 100 mg minocycline tablet twice daily for 45 days. This dosage had to be reduced to 100 mg daily from day 5 to day 8 because of vertigo. Vestibular toxicity manifesting as dizziness, ataxia and nausea is a 
